WO2005012545A3 - Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors - Google Patents

Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors Download PDF

Info

Publication number
WO2005012545A3
WO2005012545A3 PCT/US2004/023678 US2004023678W WO2005012545A3 WO 2005012545 A3 WO2005012545 A3 WO 2005012545A3 US 2004023678 W US2004023678 W US 2004023678W WO 2005012545 A3 WO2005012545 A3 WO 2005012545A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcmv
cmv
genes
viral
antivirals
Prior art date
Application number
PCT/US2004/023678
Other languages
French (fr)
Other versions
WO2005012545A2 (en
Inventor
Fenyong Liu
Walter Dunn
Cassie Chou
Original Assignee
Univ California
Fenyong Liu
Walter Dunn
Cassie Chou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Fenyong Liu, Walter Dunn, Cassie Chou filed Critical Univ California
Publication of WO2005012545A2 publication Critical patent/WO2005012545A2/en
Publication of WO2005012545A3 publication Critical patent/WO2005012545A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus

Abstract

A global functional analysis of HCMV genes is performed by constructing virus gene-deletion mutants and examining their growth phenotypes in different natural HCMV host cells. This systematic analysis of the HCMV genome identified 45 viral ORFs essential for viral replication and characterizes of 115 growth-dispensable viral genes. Of particular interest is the finding that HCMV encodes genes (temperance factors) that repress its own replication on a cell type-specific basis. In addition to HCMV, pathogen temperance may be a strategy employed by other infectious agents to enhance their long-term survivability within their respective host population.
PCT/US2004/023678 2003-07-25 2004-07-23 Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors WO2005012545A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49020003P 2003-07-25 2003-07-25
US60/490,200 2003-07-25

Publications (2)

Publication Number Publication Date
WO2005012545A2 WO2005012545A2 (en) 2005-02-10
WO2005012545A3 true WO2005012545A3 (en) 2007-08-02

Family

ID=34115371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023678 WO2005012545A2 (en) 2003-07-25 2004-07-23 Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors

Country Status (2)

Country Link
US (1) US7407744B2 (en)
WO (1) WO2005012545A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004293499B2 (en) * 2003-11-28 2009-11-26 The University Of Sydney Latent phase viral interleukin-10-(VII-10) and uses thereof
WO2007065718A1 (en) * 2005-12-08 2007-06-14 Dsm Ip Assets B.V. Protective hydrocolloid for active ingredients
WO2008011609A2 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
AU2015215948A1 (en) * 2010-05-05 2015-09-10 Ulrich Koszinowski Vaccine against beta-herpesvirus infection and use thereof
WO2011138040A2 (en) * 2010-05-05 2011-11-10 Christian Thirion Vaccine against beta-herpesvirus infection and use thereof
WO2011143653A2 (en) * 2010-05-14 2011-11-17 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
US9085808B2 (en) * 2011-01-12 2015-07-21 Abbott Molecular Inc. Materials and method for detecting cytomegalovirus (CMV)
EP2502631A1 (en) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
US9701943B2 (en) * 2011-04-15 2017-07-11 Cecilia Nauclér Genetic variant of cytomegalovirus (CMV)
LT2691530T (en) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2873861C (en) 2012-04-05 2021-01-19 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
CA2873882C (en) 2012-04-05 2020-12-15 Boehringer Ingelheim International Gmbh 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
US9505775B2 (en) 2012-11-03 2016-11-29 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
DK2964769T3 (en) 2013-03-05 2018-12-10 Univ Oregon Health & Science Cytomegalovirus vectors enabling control of T cell targeting
CN103224913B (en) * 2013-05-08 2014-05-14 中国兽医药品监察所 Duck plague live vaccine and preparation method thereof
US20160289303A1 (en) * 2013-11-15 2016-10-06 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
JP6487026B2 (en) 2014-07-16 2019-03-20 オレゴン ヘルス アンド サイエンス ユニバーシティ Human cytomegalovirus containing foreign antigen
EP4036239A1 (en) 2015-02-10 2022-08-03 Oregon Health & Science University Methods and compositions useful in generaing non canonical cd8+t cell responses
EP3377636A4 (en) * 2015-11-20 2019-11-06 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EA201990937A1 (en) 2016-10-18 2019-09-30 Орегон Хелс Энд Сайенс Юниверсити CYTOMEGAL VIRUS VECTORS SELECTING T-CELLS LIMITED BY MOLECULES OF THE MAIN HISTOCOMPATIBILITY COMPLEX E
WO2019020480A1 (en) * 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
CN109022373B (en) * 2018-08-01 2021-12-10 中国兽医药品监察所 Duck plague virus UL56 gene 3' end deletion and LORF5 gene deletion mutant strain and construction method and application thereof
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
US11217941B1 (en) * 2020-09-23 2022-01-04 All Best Precision Technology Co., Ltd. Electrical connector set, and socket and plug thereof
WO2023154905A1 (en) 2022-02-14 2023-08-17 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARCHINI A. ET AL.: "Human Cytomegalovirus with IE-2 (UL122) Deleted Fails to To Express Early Lytic Genes", JOURNAL OF VIROLOGY, vol. 75, no. 4, February 2001 (2001-02-01), pages 1870 - 1878, XP003016109 *

Also Published As

Publication number Publication date
US20050064394A1 (en) 2005-03-24
US7407744B2 (en) 2008-08-05
WO2005012545A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
WO2005012545A3 (en) Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
Wagner et al. Herpesvirus genetics has come of age
ES2526191T3 (en) Method to produce infectious influenza B virus in cell culture
EP1721985A4 (en) Nucleic acid construct containing full-length genome of human hepatitis c virus, recombinant full-length virus genome replicative cell having the nucleic acid construct transferred thereinto and method of constructing hepatitis c viral particles
Elde et al. Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses
Dunn et al. Human cytomegalovirus expresses novel microRNAs during productive viral infection
Gu et al. Analysis of synonymous codon usage in SARS Coronavirus and other viruses in the Nidovirales
Zhou et al. The genetic divergences of codon usage shed new lights on transmission of hepatitis E virus from swine to human
Umbach et al. Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2
Sanders et al. Comparative analysis of coronavirus genomic RNA structure reveals conservation in SARS-like coronaviruses
WO2000053729A3 (en) Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
WO2005062820A3 (en) Multi plasmid system for the production of influenza virus
DK0506945T3 (en) Method of gene transfer using retrotransposons
WO2001081608A3 (en) Viral vectors for use in monitoring hiv drug resistance
D’Andrea et al. A detailed comparative analysis on the overall codon usage patterns in hepatitis A virus
WO2007097820A3 (en) Viral gene products and methods for vaccination to prevent viral associated diseases
WO2006038129A3 (en) Hepatitis c virus replication system
Ziebuhr et al. Human coronavirus 229E papain-like proteases have overlapping specificities but distinct functions in viral replication
HUP0203305A2 (en) Infectious clones
DE60238309D1 (en) TOMEGALOVIRUS GENOM WITH PRESERVED WILD TYPE CHARACTERISTICS CLINICAL ISOLATE CONTAINS
UA84667C2 (en) Vaccine directed against infection induced by herpes virus of marek's disease
WO2002057437A3 (en) Generation of human cytomegalovirus yeast artificial chromosome recombinants
Fehr et al. Human cytomegalovirus gene UL21a encodes a short-lived cytoplasmic protein and facilitates virus replication in fibroblasts
CN108913684A (en) A kind of method that exogenous sequences efficiently pinpoint orientation insertion DNA virus genome
WO2003049767A3 (en) Method of large scale production of hepatitis a virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase